

Technology Development Group

Available Technologies

Contact Our Team

Permalink

Request Information

AGPAT5 as a Molecular Mediator of Insulin Resistance

Tech ID: 29036 / UC Case 2014-730-0

SUMMARY

UCLA researchers in the Departments of Medicine and Cardiology have identified a novel gene and pathway in the regulation of insulin sensitivity and discovered an inhibitor of this gene useful for treating AGPAT5-related diseases.

BACKGROUND

Insulin resistance (IR), a condition in which the body's cells fail to respond to insulin, is a significant worldwide health problem and leads to diseases such as Type-II diabetes, coronary artery disease, and fatty liver disease. The identification of efficacious therapies to improve insulin sensitivity is essential to the treatment of these metabolic diseases and conditions. However, the genetic factors that control and the variation of genetic factors that contribute to IR have not been well studied.

INNOVATION

UCLA researchers have identified a genetic variant, AGPAT isoform 5 (AGPAT5), that contributes to the development of insulin resistance in mouse models. Furthermore, they have developed an inhibitor and methodology for reducing expression of AGPAT5 mRNA and protein in vivo, allowing for the regulation of insulin and insulin sensitivity.

APPLICATIONS

- Diagnostic marker of insulin resistance
- Regulation of insulin resistance
- > Treatment of diabetes and other cardiometabolic diseases

ADVANTAGES

- ▶ Help to reverse insulin resistance
- Treatment of conditions requiring regulation of insulin sensitivity

PATENT STATUS

Country	Туре	Number	Dated	Case
United States Of America	Issued Patent	10,364,433	07/30/2019	2014-730

RELATED MATERIALS

Parks, Brian W., et al. "Genetic Architecture of Insulin Resistance in the Mouse." Cell Metabolism 21, 334. (2015).

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

Myeloperoxidase-Deficient Mouse

▶ Development Of A Method For Endocrine Network Discovery Uncovers Peptide Therapeutic Targets

CONTACT

UCLA Technology Development Group ncd@tdg.ucla.edu tel: 310.794.0558.



INVENTORS

Lusis, Aldons J.

OTHER INFORMATION

KEYWORDS

diabetes, metabolic diseases, genetic

diseases, insulin resistance,

cardiometabolic disease, coronary

artery disease, cardiovascular,

obesity, metabolic syndrome

CATEGORIZED AS

Medical

- Disease: Cardiovascular
- and Circulatory System
- Disease: Genetic Diseases
- and Dysmorphic Syndromes
- Disease:
- Metabolic/Endocrinology
- Therapeutics

RELATED CASES

2014-730-0

UCLA Technology Development Group

 $^{\odot}$ 2017 - 2019, The Regents of the University of California

Terms of use

https://tdg.ucla.edu

Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu

10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095

Privacy Notice

